Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2566 to 2580 of 8910 results

  1. Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatments (managed access review of TA1023) [ID6653]

    Topic prioritisation

    Technology appraisal guidance
    Topic prioritisation

  2. Monofocal intraocular lenses for cataract surgery (provisional title)

    In development Reference number: GID-HTE10090 Expected publication date: TBC

    Health technology evaluations
    In development

  3. Surgical mesh for treatment of non-primary ventral hernias

    Awaiting development Reference number: GID-HTG10165 Expected publication date: TBC

    HealthTech guidance
    Awaiting development

  4. Percutaneous thrombectomy for intermediate-risk or high-risk pulmonary embolism

    In development Reference number: GID-HTG10169 Expected publication date: TBC

    HealthTech guidance
    In development

  5. Mevrometostat with enzalutamide for treating hormone-relapsed metastatic prostate cancer after abiraterone acetate [ID6677]

    Awaiting development Reference number: GID-TA11827 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Luspatercept for treating anaemia caused by myelofibrosis [ID6697]

    Awaiting development Reference number: GID-TA11915 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Tozorakimab for treating exacerbations of chronic obstructive pulmonary disease after optimised inhaled dual or triple therapy [ID6711]

    Awaiting development Reference number: GID-TA11944 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Rusfertide for treating polycythaemia vera in people having phlebotomy [ID6709]

    Awaiting development Reference number: GID-TA11937 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. AI technologies to aid the scoring and interpretation of diagnostic sleep studies

    Awaiting development Reference number: GID-HTG10174 Expected publication date: TBC

    HealthTech guidance
    Awaiting development

  10. Technologies for the detection of Hepatocellular Carcinoma

    Awaiting development Reference number: GID-HTG10175 Expected publication date: TBC

    HealthTech guidance
    Awaiting development

  11. Technology for cancer case finding using primary care records

    Awaiting development Reference number: GID-HTG10176 Expected publication date: TBC

    HealthTech guidance
    Awaiting development

  12. ProKnow cloud-based system for radiotherapy data storage, communication and management

    Awaiting development Reference number: GID-HTG10178 Expected publication date: TBC

    HealthTech guidance
    Awaiting development

  13. Genedrive MT-RNR1 ID Kit for detecting a genetic variant to guide antibiotic use and prevent hearing loss in babies

    Awaiting development Reference number: GID-HTG10177 Expected publication date: TBC

    HealthTech guidance
    Awaiting development

  14. Giredestrant with everolimus for treating oestrogen-receptor positive HER2-negative advanced breast cancer after cyclin-dependent kinase 4 and 6 inhibitor and endocrine treatment [ID6576]

    Awaiting development Reference number: GID-TA11773 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Tarlatamamb for treating extensive stage small-cell lung cancer that has progressed after platinum-based chemotherapy [ID6617]

    In development Reference number: GID-TA11812 Expected publication date: TBC

    Technology appraisal guidance
    In development